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Abstract
Introduction: The carriers of the same autosomal recessive disorder are usually unaware of onset
of the genetic diseases in the children even if screenings are available for many of these
disorders. In this paper, we report the experience of the Prenatal Diagnosis Center of AOU
Federico II and we discuss the role of the screening for beta-thalassemia (BT), cystic fibrosis (CF)
and for other rare genetic disorders.
Materials and Methods: We analyzed retrospectively the indication for Prenatal Diagnosis (PD) of
all the couples referred to our center from January 1993 to May 2013. We divided our sample
into three groups: couples at high risk for BT, for CF and for other rare genetic disorders.
Results: From January 1993 to May 2013, we performed 1269 PD for genetic disorders. There are
still couples who discovered to be carriers of BT by screening after the birth of the affected
child (n¼ 51 (11,3%)); the majority of the people were screened for CF carrier after the birth of
an affected child (n¼ 155 (80,7%)) or through the cascade screening (n¼ 28 (14,6%)). Large-
scale screenings for rare genetic conditions are not available and people were screened only if
they have a positive familial history.
Conclusion: Parental screening is available for many severe and rare diseases whose genetic
origin is known. The proportion of patients referred for very high-risk indications increased over
time with an higher demand for rare disease. An adequate counseling is fundamental to
identify women at risk for having affected child. Screening, counseling and PD of genetic
diseases is a complex matter and needs for a continuous update.
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Introduction
Public demand for prenatal screening, counseling and prenatal
diagnosis (PD) of genetic diseases has increased during the past
decade worldwide. PD is an area where technology is a
advancing rapidly offering an increasing array of tests to
women getting information about the health of the fetus. Many
of this genetic disorder are life-threatening or chronically
debilitating diseases. The carriers of the same autosomal
recessive disorder are usually unaware of onset of the genetic
diseases in the children even if screenings are available for
many of these disorders. The aim of the screening is to enable
carrier couples to be informed of the risk of having an affected
child, making possible consideration of all reproductive
options. Preconceptional consultation in primary care is
fundamental to identify couple at risk for genetic disorders, to
propose the available preconceptional screenings and to start
pregnancy conscious of all the possible risks [1]. The most
widespread carrier screenings are those for beta-thalassemia
(BT) and cystic fibrosis (CF), that are the two most frequent
genetic disorders in our area. However, large-scale screenings
for rare genetic conditions are not available and people were
screened only if they have a positive familial history. In this
paper, we report the experience of the Prenatal Diagnosis
Center of AOU Federico II and we discuss the role of the
screening for BT and CF and for other rare genetic disorders,
highlighting important ethical and socio-economical issues
related to genetic counseling and parental screening.
Materials and methods
We analyzed retrospectively the indication for PD of all
the couples referred to our center from January 1993 to
May 2013. We divided our sample into three groups: couples at
high risk for BT, for CF and for other rare genetic disorders.
The Rare Diseases Act of 2002 defines rare disease any disease
generally considered to have a prevalence of fewer than
200 000 affected individuals in the United States [2].
Differences among groups were evaluated using Chi-square
test for categorical variables and ANOVA test for continuous
variables. The indications for parental screening were retro-
spectively collected. Data were analyzed by SPSS 18.0.
Results
From January 1993 to May 2013, we performed 1269 PD for
genetic disorders. Among these, 190 (14.9%) were amnio-
centesis and 1079 (85.1%) were chorionic villus samples
(CVS). 528 (41.6%) couples were referred to our centre
for PD of BT, 192 (15.1%) underwent a PD for CF and 549
(43.3%) for other rare genetic disorders. Clinical and
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anamnestic characteristics of each group were reported in
Table 1. The group of rare genetic disorders includes more
than 70 different diseases; the frequencies of genetic disorders
stratified by prevalence are reported in Table 2. 69 (12.6%)
out of 549 PD were performed for autosomal dominant
diseases, 237 (43.2%) for autosomal recessive diseases and
243 (43.2%) for recessive X-linked disease. Indications for
parental screening were reported in Table 3. For 77 (14.6%)
out of 528 couples carriers of BT, data were missed, while
we did not have missing data among FC carriers couples and
for the group of rare genetic disorders.
Discussion
In this paper, we describe our experience on the role of parental
screening for different genetic disorders in a population of
pregnant women booked for PD. For a better understanding of
the role of the prenatal screening in each situation we decide
to divide our sample into three groups: couples at high risk
for BT, for CF and for rare genetic disorders. BT and CF are
the most common genetic disorders in our area and a parental
screening is well accepted; the low incidence of the rare
genetic disorder does not give space to a large scale screening.
The increased demand for genetic counseling and prenatal
diagnosis genetic and rare diseases observed in these last years
was registered also in our Center [3].
As shown in Table 3, there are still couples who discovered
to be carriers of BT by screening after the birth of the affected
child; the percentage of these couples is really low because
our region is an endemic area where the cost-effectiveness
of prenatal screening is widely approved. The screening tests
Table 2. Number of PD for rare genetic disorders stratified by prevalence (number of cases).
41:50 000 N¼ 372 (67.8%) 1:50 000–1:100 000 N¼ 99 (18.0%) 51:100 000 N¼ 78 (14.2%)
Acondroplasia (11)
Alpha-thalassemia (6)
Angelman Syndrome (6)
Autosomal dominant deafness 3A (5)
Centronuclear myopathy (3)
Congenital 21-OH deficiency (12)
Congenital Disorders of Glycosilation 1a (1)
Facioscapulohumeral muscolar dystrophy 1 (1)
Familial Adenomatous Polyposis I (1)
Fragile X Syndrome (40)
Glycine encephalopathy (3)
Haemophilia A and B (63)
Huntington’s Disease (11)
Myotonic Dystrophy Type 1 (16)
Muscular Dystrophy (99)
Neuromuscular ceroid lipofuscinosis (1)
Ornithine Transcarbamylase Deficiency (4)
Propionic Acidemia (2)
Phenylketonuria (10)
Pyruvate Kinase Deficiency (1)
Rett Syndrome (3)
Spinal Muscolar Atrophy (57)
Spinocerebellar Ataxia 3 (4)
Tuberous Sclerosis (9)
Von Hippel-Lindau Disease (1)
X-Linked hydrocephalus (2)
Argininosuccinic Aciduria (5)
Carbonic Anhydrase II deficiency (2)
Choroideremia (2)
Friedreich’s Ataxia (1)
Galactosemia (3)
Glycogen Storage Disease Type Ib,
II and III (13)
Holt-Oram Syndrome (2)
Krabbe Leukodystrophy (8)
Lynphoisticytosis (1)
MEN 1 e 2 (3)
Methylmalonic Aciduria (14)
Mucopolysaccharidosis Type I, IIIA
and IIIB (17)
Papillon-Leage-Psaume Syndrome (1)
Propionic Acidemia (2)
SCID (5)
Shwachman Diamond Syndrome (1)
Smith-Lemli-Opitz (11)
Spinocerebellar Ataxia 1 and 2 (5)
Zellweger Syndrome (3)
APECED Syndrome (1)
Bruton’s disease (2)
Canavan Disease (5)
Carbamoyl phosphate synthetase
deficiency (3)
Pyruvate CarboxilaseDeficiency (1)
Ethylmalonic encephalopathy (2)
Fanconi Anemia (6)
Glycogen Storage Disease Type IV (2)
Gangliosidosis Type 1 and 2 (7)
HHH Syndrome (1)
Lesch-Nyhan syndrome (4)
Lysinuric Protein Intolerance (1)
Maple syrup urine disease type II (1)
Metatropic Dysplasia (1)
Molybdenum cofactor deficiency (1)
Mucopolysacharidosis Type II (19)
Niemann-Pick Disease (11)
Nonketonic hyperglycinemia (6)
Progeria (1)
Schimke immuno-osseous dysplasia (1)
Wiskott Aldrich Syndrome (2)
Table 1. Clinical and anamnestic characteristics of women at risk for having a children affected by BT, FC and
other rare genetic disorders.
Variable FC N¼ 192 (15.1%) BT N¼ 528 (41.6%)
Rare genetic disorders
N¼ 549 (43.3%)
Age*
Years (mean SD) 31.4 0.4 29.2 0.2 30.8 0.2
Amniocentesis*
N (%) 17 (8.9%) 45 (8.5%) 148 (26.1%)
Gestational age
Weeks (mean SD) 18.6 3.9 17.7 2.2 17.3 2.1
CVS*
N (%) 175 (91.1%) 483 (91.5%) 421 (73.9%)
Gestational age
Weeks (mean SD) 11.5 1.2 11.5 1.4 11.8 1.3
41 PD in our center*
N (%) 72 (37.5%) 292 (58.3%) 232 (40.8%)
Twin pregnancies
N (%) 2 (1.0%) 8 (1.5%) 3 (0.5%)
Number of pregnancies*
Median 3 2 2
*p50.001 (ANOVA Test).
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are based on accurate measurements of hematological param-
eters, iron deficiency evaluation and separation of Hb fraction
[4]. Even if screening should be offered to all women of
childbearing age, the percentage of screening occurred during
pregnancy is still high.
Contrary to BT, the majority of the people were screened
for CF carrier after the birth of an affected child or through
the cascade screening, while the percentage of couples who
performed a preconceptional screening is really low. Fetal
bowel ultrasound abnormalities are reported among the
indications for the screening because bowel hyper echogeni-
city and loop dilation are associated with a risk of CF of about
3% [5]. Cascade screening is a mechanism for identifying
people at risk for a genetic condition by a process of
systematic family tracing. For this reason, in our series
couples at risk for CF required a PD later than ones at risk
for BT (Table 1). Even if a consensus conference at NIH
recommended, since 1997, that CF carrier screening should
be offered to all pregnant couples and those contemplating
pregnancy [6], there are many difficult correlated to the
introduction of a large-scale screening. First of all, there is an
inability to identify carriers by clinical or biochemical means
and the only possibility is the genetic test, with high costs
for the couple. Moreover, the big heterogeneity of CTFR
mutations interferes with the implementation of screening.
Since the discovery of the first CFTR mutation (F805del) in
1989, more than 1900 different changes have been found in
this gene, while the American College of Medical Genetic
proposed a 25 mutation panel for the screening [7]. This panel
is very sensitive for Ashkenazi Jewish descendents (97%)
and less sensitive for Southern Europe (70%). Therefore, in
addition to the screening for frequent mutations, according to
the European recommendations, a complementary panel
may be required to test population-specific mutations with a
frequency above 1%; for this reason, up to 2001, we include
five mutations peculiar to Southern Italy [8]. However,
because screening is offered only for the more frequent
mutations, a negative screening does not exclude the chance
of being a CF carrier. Many studies demonstrated that often
people misunderstand CF carrier screening results and they
underestimate the residual risk [9]. Moreover, many CFTR
mutations are of unknown clinical significance making really
difficult the genetic counseling. The different survival rate of
people affected by CF through the years must be discussed
with the couple. Only thirty years ago, a CF patient was not
expected to reach adulthood, while, nowadays, many people
even live into their fifties and sixties.
In the group of rare genetic disease, the genetic study of the
high risk couples was always performed after the birth of an
affected child or for a positive familiar history; it is impossible
to offer a parental screening for all known possible genetic
disorders to the pregnant population. More than 70 different
genetic diseases are included (Table 2) in PD of our Center and
78 (14.2%) procedures were performed for diseases with an
prevalence less than 1 in 100 000. The demand for screening for
extremely rare diseases is increasing, giving points for
reflection on other important ethical issues; variable expres-
sivity, genotype-phenotype variability, adult or early onset
disease are issues that often makes really difficult the genetic
counseling and the performance of the PD. For these reasons, it
is really important to offer the screening and the PD after a
complete counseling, to explain all the performance of PD and
all the possible options of the procedure. Couples should be
aware that often the results of PD are not able to predict the age
of onset, the clinical course or the degree of disability.
Moreover, relevant in the counseling is the explanation of the
type of disease, of clinical signs, onset of disease, outcome and
possible therapy. The consultant and the obstetric must outline
to the high risk couples the options of the single specific
genetic disorders. For example, there are no more indications
for PD of the autosomic recessive disease Phenylketonuria
because we know that diet influence phenotypic expression.
Dietary protein restriction and supplementation with phenyl-
alanine-free medical foods are good solutions for a normal
neurological development. There is a mandatory neonatal
screening that give us the possibility to perform a diagnosis
within 48–72 h from the birth.
Other criticism arise from some autosomal dominant
disease. The Familial Adenomatous Polyposis (FAP), an
autosomal dominant disease is characterised by predisposition
to late onset colon polyposis and colorectal cancer, caused by
germline mutations in the APC gene. The FAP prophylaxis
is possible and consists of resection of the entire large bowel,
to prevent malignant transformation, but these surgical
procedures shorten the life expectancy and reduce the quality
of life. We may think if is ethically correct to perform
this diagnosis in a family with history of disease in one of the
parents.
In many cases of autosomal dominant disease, when the
mother is affected, PD has a central role for a correct
management of pregnancy. For example, for women with a
diagnosis of MEN 2A, it has recently been shown that PD
and a correct management could improve survival and
outcome drastically reducing maternal and fetal mortality.
RET mutations are associated with three risk levels of
developing medullary thyroid carcinoma and pheochromocy-
toma. Therefore, genetic counseling and PD are mandatory to
assuring parents on the life-long risk of tumors, avoiding
psychological distress that can further complicate pregnancy
in affected women [10].
Table 3. Indications for Parental screening.
Indications CF N¼ 182 BT N¼ 451 Rare genetic disorders N¼ 549
Affected child(ren) N (%) 155 (80.7%) 51 (11.3%) 190 (34.6%)
Cascade screening N (%) 28 (14.6%) 41 (9.1%) 251 (45.7%)
Prenatal screening N (%) – 153 (33.4%) –
Preconceptional screening N (%) 5 (2.6%) 206 (45.7%) –
Fetal bowel ultrasound abnormalities N (%) 4 (2.2%) – –
One parent affected N (%) – – 108 (19.8%)
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Another important issue in genetic counseling is the
possible residual risk after molecular testing. For example,
in couple at risk for Spinal Muscolar Atrophy, reported in
our series in 57 cases (10.4%), the sensitivity of the molecular
test is 93–95%; therefore, carrier test does not always identify
the disease because parents may be carriers of rare subtle
mutations and, moreover, the occurrence of extremely rare
de novo mutations is possible [11]. Therefore, the physician
must highlight the possible residual risk.
Important ethical issues are related to adult onset of the
diseases, like Huntington’s Disease (HD). It is a dominantly
inherited human neurodegenerative disorder characterized by
motor deficits, cognitive impairment, and psychiatric symp-
toms leading to inexorable decline and death, starts generally
in every age [12]. It has an incidence of 1 in 25 000 people.
In all the couples undergoing the PD, there was one parent
affected, screened because of a positive familiar history.
This test is available since 1993, when the gene involved in
HD was discovered. It gives the possibility to confirm the
diagnosis in case of people with symptoms that suggest HD or
to inform a person that could develop the disease during
his life. This test cannot give information about the severity
of the syndrome or the age of development of the disease.
The obstetricians and the geneticists must outline during the
counseling the variability of phenotype and the interaction
between age of onset, symptomatology and penetrance.
In Huntington’s disease, as in other adult onset disorders,
the physician must take into account when counseling the
possibility that the parents will declare a wish to continue
with the pregnancy despite a positive prenatal test result; this
presents other ethical questions [13]. In fact, on one hand it
could prevail the parents’ right to know the genetic status of
their future yet unborn child for a late onset genetic disorder,
on another hand it could prevail the right of the future child
not to know a genetic diagnosis, or to decide for oneself when
to have a diagnosis. This is very important, particularly in
case where there is no cure for a condition.
In conclusion, parental screening is available for many
severe and rare diseases whose genetic origin is known; the
our PD Unit in collaboration with CEINGE is part of an
International Network for the diagnosis of all the diseases
whose genetic diagnosis is possible. The proportion of
patients referred for very high-risk indications increased
over time with an higher demand for rare disease. We
observed an increment of the numbers of the prenatal invasive
procedures and an increment of variation of the type of
disease for which the PD is possible. It is impossible to screen
women at childbearing age for all the possible genetic
disorders; for this reason an adequate anamnesis and coun-
seling is fundamental to identify women at risk for having
affected child. A multidisciplinar team of prenatal diagnosis
with a gynecologist, a genetic medical, a molecular biology
medical and psychologist is necessary for the relevance of the
disease. The members of the team must pay more attention
in the counseling to the moral character of choices about
prenatal diagnosis. Genetic counseling must promote appro-
priate and medical interventions when available and facilitate
personal decision making when interventions are supportive.
In any case screening, counseling and PD of genetic diseases
is a complex matter and needs of a continuous updates.
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